Expression of the class II tumor suppressor gene RIG1 is directly regulated by p53 tumor suppressor in cancer cell lines

被引:26
|
作者
Hsu, Tzu-Hui [2 ]
Chu, Chin-Chen [3 ,4 ]
Jiang, Shun-Yuan [5 ]
Hung, May-Whey [6 ]
Ni, Wen-Chieh [1 ]
Lin, Huai-En [1 ]
Chang, Tsu-Chung [1 ,2 ]
机构
[1] Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan
[2] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan
[3] Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Taiwan
[4] Chia Nan Univ Pharm & Sci, Dept Recreat & Hlth Care Management, Tainan, Taiwan
[5] Buddhist Tzu Chi Gen Hosp, Dept Med Educ & Res, Taipei, Taiwan
[6] Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan
关键词
Retinoid-inducible gene 1; Retinoic acid receptor responder 3; Tazarotene-induced gene 3; p53; Class II tumor suppressor; TRANSCRIPTIONAL TARGET; DNA; GROWTH; IDENTIFICATION; PHOSPHATASE; ACTIVATION; CARCINOMA; RARRES3; CLONING;
D O I
10.1016/j.febslet.2012.03.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies indicated that the RIG1 (RARRES3/TIG3) plays an important role in cell proliferation, differentiation, and apoptosis. However, the regulatory mechanism of RIG1 gene expression has not been clearly elucidated. In this study, we identified a functional p53 response element (p53RE) in the RIG1 gene promoter. Transfection studies revealed that the RIG1 promoter activity was greatly enhanced by wild type but not mutated p53 protein. Sequence specific mutation of the p53RE abolished p53-mediated transactivation. Specific binding of p53 protein to the rig-p53RE was demonstrated using electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay. Further studies confirmed that the expression of RIG1 mRNA and protein is enhanced through increased p53 protein in HepG2 or in H24-H1299 cells. In conclusion, our results indicated that RIG1 gene is a downstream target of p53 in cancer cell lines. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:1287 / 1293
页数:7
相关论文
共 50 条
  • [41] The expression of p53 tumor suppressor gene in breast cancer cells is down-regulated by cytokine oncostatin M
    Liu, JW
    Li, C
    Ahlborn, TE
    Spence, MJ
    Meng, L
    Boxer, LM
    CELL GROWTH & DIFFERENTIATION, 1999, 10 (10): : 677 - 683
  • [42] Tumor suppressor p53 and metabolism
    Liu, Juan
    Zhang, Cen
    Hu, Wenwei
    Feng, Zhaohui
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) : 284 - 292
  • [43] p53: not just a tumor suppressor
    Oren, Moshe
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (07) : 539 - 543
  • [44] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205
  • [45] Effects of tumor suppressor gene (p53) on brain tumor angiogenesis and expression of angiogenic modulators
    Tse, V
    Yung, Y
    Santarelli, JG
    Juan, D
    Hsiao, M
    Haas, M
    Harsh, G
    Silverberg, G
    ANTICANCER RESEARCH, 2004, 24 (01) : 1 - 10
  • [46] Drosophila p53 tumor suppressor directly activates conserved asymmetric
    Manzanero-Ortiz, Sandra
    Franco, Maribel
    Laxmeesha, Mahima
    Carmena, Ana
    ISCIENCE, 2024, 27 (11)
  • [47] Cell-mediated cytotoxicity can be regulated by p53 tumor suppressor gene activity in vitro
    Mahdi, T
    Tanzer, J
    Brizard, A
    Guilhot, F
    Babin, P
    Kitzis, A
    BIOLOGY OF THE CELL, 1995, 84 (03) : 175 - 185
  • [48] p53 tumor suppressor protein regulates the levels of huntingtin gene expression
    Z Feng
    S Jin
    A Zupnick
    J Hoh
    E de Stanchina
    S Lowe
    C Prives
    A J Levine
    Oncogene, 2006, 25 : 1 - 7
  • [49] Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium
    Tan, DTH
    Lim, ASM
    Goh, HS
    Smith, DR
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 123 (03) : 404 - 405
  • [50] p53 tumor suppressor protein regulates the levels of huntingtin gene expression
    Feng, Z
    Jin, S
    Zupnick, A
    Hoh, J
    de Stanchina, E
    Lowe, S
    Prives, C
    Levine, AJ
    ONCOGENE, 2006, 25 (01) : 1 - 7